Gelteq (GELS) Competitors $1.40 -0.02 (-1.41%) As of 09:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GELS vs. BMEA, DRRX, ICCC, VRCA, ANL, ZIVO, IFRX, BRNS, LTRN, and HOWLShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Biomea Fusion (BMEA), DURECT (DRRX), ImmuCell (ICCC), Verrica Pharmaceuticals (VRCA), Adlai Nortye (ANL), ZIVO Bioscience (ZIVO), InflaRx (IFRX), Barinthus Biotherapeutics (BRNS), Lantern Pharma (LTRN), and Werewolf Therapeutics (HOWL). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Its Competitors Biomea Fusion DURECT ImmuCell Verrica Pharmaceuticals Adlai Nortye ZIVO Bioscience InflaRx Barinthus Biotherapeutics Lantern Pharma Werewolf Therapeutics Biomea Fusion (NASDAQ:BMEA) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends. Is BMEA or GELS more profitable? Gelteq's return on equity of 0.00% beat Biomea Fusion's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -243.95% -140.74% Gelteq N/A N/A N/A Do insiders & institutionals have more ownership in BMEA or GELS? 96.7% of Biomea Fusion shares are held by institutional investors. 18.4% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend BMEA or GELS? Biomea Fusion currently has a consensus target price of $16.80, indicating a potential upside of 897.03%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 3.17Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, BMEA or GELS? Gelteq has higher revenue and earnings than Biomea Fusion. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$138.43M-$3.03-0.56Gelteq$100K132.16-$2.33MN/AN/A Does the media favor BMEA or GELS? In the previous week, Biomea Fusion had 7 more articles in the media than Gelteq. MarketBeat recorded 8 mentions for Biomea Fusion and 1 mentions for Gelteq. Gelteq's average media sentiment score of 0.94 beat Biomea Fusion's score of 0.51 indicating that Gelteq is being referred to more favorably in the news media. Company Overall Sentiment Biomea Fusion Positive Gelteq Positive SummaryBiomea Fusion beats Gelteq on 7 of the 12 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.22M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2925.74Price / Sales132.16356.37470.66115.79Price / CashN/A43.0338.2159.48Price / Book1.088.608.846.15Net Income-$2.33M-$54.65M$3.25B$265.06M7 Day Performance-15.66%5.86%3.72%2.60%1 Month Performance-19.08%8.86%5.86%2.83%1 Year PerformanceN/A13.33%30.23%25.58% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.40-1.4%N/AN/A$13.22M$100K0.00N/ABMEABiomea Fusion3.6717 of 5 stars$1.60+0.3%$17.00+965.8%-69.0%$59.47MN/A-0.5250DRRXDURECT1.8571 of 5 stars$1.86flatN/A+42.9%$57.73M$2.03M-12.4080Earnings ReportShort Interest ↓ICCCImmuCell0.5624 of 5 stars$6.35+2.5%N/A+90.9%$57.36M$26.49M-90.6370News CoverageEarnings ReportShort Interest ↓VRCAVerrica Pharmaceuticals4.5955 of 5 stars$6.13+0.2%$80.00+1,205.1%-80.3%$56.70M$7.18M-0.5140Earnings ReportShort Interest ↓ANLAdlai Nortye1.3803 of 5 stars$1.53-1.0%$9.00+486.7%-46.7%$56.61MN/A0.00127Short Interest ↑Gap DownZIVOZIVO Bioscience0.2562 of 5 stars$14.49+3.5%N/A+112.4%$55.31M$15.85K-2.9710News CoverageGap DownIFRXInflaRx3.2576 of 5 stars$0.82-2.6%$6.60+706.8%-38.7%$54.92M$129.75K-1.0060Gap DownBRNSBarinthus Biotherapeutics2.4448 of 5 stars$1.33+1.1%$6.25+371.7%-4.1%$53.61M$14.97M-0.81107Negative NewsShort Interest ↑LTRNLantern Pharma2.7136 of 5 stars$4.94-4.0%$25.00+406.5%+16.0%$53.24MN/A-2.6820Earnings ReportGap UpHOWLWerewolf Therapeutics3.7308 of 5 stars$1.18-1.3%$8.33+609.2%-33.7%$52.95M$1.88M-0.7140News CoverageEarnings Report Related Companies and Tools Related Companies Biomea Fusion Competitors DURECT Competitors ImmuCell Competitors Verrica Pharmaceuticals Competitors Adlai Nortye Competitors ZIVO Bioscience Competitors InflaRx Competitors Barinthus Biotherapeutics Competitors Lantern Pharma Competitors Werewolf Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access